The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis

EJNMMI Research

Table 1 Estimates of the SMD as summary measure for the difference in [18F]FDG (SUV_max) uptake between negative versus positive IHC expression of ER, PR, HER2, and Ki-67

Receptor	Studies	Patients		Meta-analysis				Subgroup	Egger
Receptor	No	Negative	Positive	I² (%)	SMD	95% CI	P	P	P
Primary analyses
ER	31	1659	3777	48.0	0.66	0.56, 0.77	< 0.0001	–	0.6530
PR	30	2043	2788	71.6	0.56	0.40, 0.71	< 0.0001	–	0.7426
HER2	32	4035	1664	80.0	− 0.29	− 0.49, − 0.10	0.0043	–	0.4726
Ki-67	19	1720	2186	57.8	− 0.77	− 0.93, − 0.61	< 0.0001	–	0.8838
Sensitivity analyses
ER	47	2181	5256	43.1	0.67	0.59, 0.75	< 0.0001	0.7980	0.7934
PR	46	2764	4171	66.4	0.54	0.42, 0.65	< 0.0001	0.6328	0.8925
HER2	49	5602	2221	74.5	− 0.30	− 0.43, − 0.16	< 0.0001	0.9322	0.6184
Ki-67	28	2187	3028	51.0	− 0.75	− 0.87, − 0.64	< 0.0001	0.5364	0.7299

Data derived from the primary and sensitivity analyses are presented
CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor 2 receptor; PR, progesterone receptor; SMD, standardized mean difference